Duchenne Muscular Dystrophy
Entrada Therapeutics Inc. focuses its clinical research on Duchenne muscular dystrophy, with studies targeting patients whose disease is amenable to exon 44 skipping and exon 45 skipping.
- Neuromuscular disease
- Genetic muscle disorders
- Exon skipping therapies
The sponsor’s active trial portfolio includes recruiting studies across multiple countries and research sites, reflecting a concentrated interest in treatment areas relevant to DMD and its molecular subtypes.
Muscle Function and Disease Progression
Its clinical research activity is centered on preserving skeletal muscle function and addressing the progressive weakness associated with Duchenne muscular dystrophy.
- Muscle degeneration
- Motor impairment
- Progressive neuromuscular decline
These studies align with therapeutic interests in the clinical management of muscle loss, mobility limitation, and disease-related functional deterioration.
Genotype-Directed Therapeutics
The sponsor’s programs are directed toward mutation-specific approaches in Duchenne muscular dystrophy, particularly patients eligible for exon 44 or exon 45 skipping.
- RNA-targeted therapy
- Mutation-specific treatment
- Precision medicine
This area of interest reflects a focus on therapies tailored to defined genetic subgroups within the broader muscular dystrophy population.
Clinical Safety and Tolerability
Across its current studies, Entrada Therapeutics Inc. is evaluating the safety and tolerability of investigational therapies in participants with Duchenne muscular dystrophy.
- Treatment safety
- Therapeutic tolerability
- Patient monitoring
Its research activity is concentrated in neuromuscular medicine, with ongoing attention to clinical outcomes relevant to long-term treatment use.
